Trial Profile
A Double-Blind, Randomised, Placebo-Controlled Study to Assess the Safety of Cat-PAD in Cat Allergic Subjects With Controlled Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Cat SPIRE (Primary)
- Indications Asthma; Rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Circassia; Niox
- 26 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 11 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned end date changed from 1 Oct 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.